The Effect of Price Caps on Advertising to Physicians: Evidence from the 340b Drug Pricing Program

References

• Agha L, Zeltzer D (2022) Drug diffusion through peer networks: The influence of industry payments. Amer. Econom. J. Econom. Policy 14(2):1–33.Crossref, Google Scholar
• Alpert A, Evans WN, Lieber EMJ, Powell D (2022) Origins of the opioid crisis and its enduring impacts. Quart. J. Econom. 137(2):1139–1179.Crossref, Google Scholar
• Azoulay P (2002) Do pharmaceutical sales respond to scientific evidence? J. Econom. Management Strategy 11(4):551–594.Crossref, Google Scholar
• Berger B (2023) How do health systems capitalize on public programs? Side effects of the 340B drug pricing program. Working paper, Harvard University, Cambridge, MA.Google Scholar
• Bond AM, Dean EB, Desai SM (2023) The role of financial incentives in biosimilar uptake in Medicare: Evidence from the 340B program: Study examines the role of financial incentives in the uptake of biosimilar drugs in Medicare. Health Affairs 42(5):632–641.Crossref, Google Scholar
• Bruno JP, Carey C, Nikpay S (2024) Does 340B status affect pharmacy demand? Evidence from Medicare Part D plans. Working paper, Cornell University, Ithaca, NY.Google Scholar
• Carey C, Lieber EMJ, Miller S (2021) Drug firms’ payments and physicians’ prescribing behavior in Medicare Part D. J. Public Econom. 197:104402. Crossref, Google Scholar
• Centers for Medicare and Medicaid Services Open payments data (2014–2019) (2023) Dataset. Retrieved June 9 2023, https://openpaymentsdata.cms.gov/.Google Scholar
• Chambers JD, Thorat T, Wilkinson CL, Neumann PJ (2017) Drugs cleared through the FDA’s expedited review offer greater gains than drugs approved by conventional process. Health Affairs 36(8):1408–1415.Crossref, Google Scholar
• Ching A, Ishihara M (2010) The effects of detailing on prescribing decisions under quality uncertainty. Quant. Marketing Econom. 8(2):123–165.Crossref, Google Scholar
• Ching AT, Ishihara M (2012) Measuring the informative and persuasive roles of detailing on prescribing decisions. Management Sci. 58(7):1374–1387.Link, Google Scholar
• Ching AT, Clark R, Horstmann I, Lim H (2016) The effects of publicity on demand: The case of anti-cholesterol drugs. Marketing Sci. 35(1):158–181.Link, Google Scholar
• Chintagunta PK, Goettler RL, Kim M (2012) New drug diffusion when forward-looking physicians learn from patient feedback and detailing. J. Marketing Res. 49(6):807–821.Crossref, Google Scholar
• Cubanski J, Neuman T, Freed M (2023) Explaining the prescription drug provisions in the inflation reduction act. Kaiser Family Foundation (January 24), https://www.kff.org/medicare/issue-brief/explaining-the-prescription-drug-provisions-in-the-inflation-reduction-act/.Google Scholar
• Dartmouth Atlas (2024) Research methods. Dartmouth Atlas Project, The Trustees of Dartmouth, Lebanon, NHGoogle Scholar
• Datta A, Dave D (2017) Effects of physician-directed pharmaceutical promotion on prescription behaviors: Longitudinal evidence: Physician-directed Rx promotion and prescription behaviors. Health Econom. 26(4):450–468.Crossref, Google Scholar
• Desai S, McWilliams JM (2018) Consequences of the 340B drug pricing program. New England J. Medicine 378(6):539–548.Crossref, Google Scholar
• Dickson S, Gabriel N, Hernandez I (2023) Trends in proportion of Medicare Part D claims subject to 340B discounts, 2013-2020. JAMA Health Forum 4(11):e234091.Crossref, Google Scholar
• Dong X, Chintagunta PK, Manchanda P (2011) A new multivariate count data model to study multi-category physician prescription behavior. Quant. Marketing Econom. 9(3):301–337.Crossref, Google Scholar
• Dong X, Manchanda P, Chintagunta PK (2009) Quantifying the benefits of individual-level targeting in the presence of firm strategic behavior. J. Marketing Res. 46(2):207–221.Crossref, Google Scholar
• Everhart A, Landon B, Normand S-L (2022) Manufacturer payments to physicians: Information, persuasion, and the adoption of new medical technologies. Working paper, Harvard Medical School, Cambridge, MA.Google Scholar
• Fein AJ (2020) New HRSA data: 340B program reached $29.9 billion in 2019; now over 8% of drug sales. Drug Channels (June 9), https://www.drugchannels.net/2020/06/new-hrsa-data-340b-program-reached-299.html.Google Scholar
• Frank RG, Salkever DS (1992) Pricing, patent loss and the market for pharmaceuticals. Southern Econom. J. 59(2):165–179.Crossref, Google Scholar
• Gray C (2023) The incidence of the 340B program: The effects of contract pharmacies on Part D premiums and reimbursements. Working paper, The Wharton School, University of Pennsylvania, Philadelphia.Google Scholar
• Grennan M, Myers K, Swanson A, Chatterji A (2025) No free lunch? Welfare analysis of firms selling through expert intermediaries. Rev. Econom. Stud. 92(4):2357–2577.Google Scholar
• Guo T, Sriram S, Manchanda P (2020) “Let the sunshine in”: The impact of industry payment disclosure on physician prescription behavior. Marketing Sci. 39(3):516–539.Link, Google Scholar
• Guo T, Sriram S, Manchanda P (2021) The effect of information disclosure on industry payments to physicians. J. Marketing Res. 58(1):115–140.Crossref, Google Scholar
• Han D (2018) Hospital financial outcomes under the 340B drug pricing program: A tale of two payment systems. Working paper, National University of Singapore, Singapore.Google Scholar
• Ji Y, Rogers P (2024) The long-run impacts of regulated price cuts: Evidence from Medicare. NBER Working Paper No. 33083, National Bureau of Economic Research, Cambridge, MA.Google Scholar
• Kakani P, Chernew M, Chandra A (2020) Rebates in the pharmaceutical industry: Evidence from medicines sold in retail pharmacies in the U.S. NBER Working Paper No. 26846, National Bureau of Economic Research, Cambridge, MA.Google Scholar
• Keller KO, Guyt JY, Grewal R (2024) Soda taxes and marketing conduct. J. Marketing Res. 61(3):393–410.Crossref, Google Scholar
• King R (2022) Bristol Myers Squibb becomes 12th drugmaker to announce 340B contract pharmacy restrictions. Fierce Healthcare (January 19), https://www.fiercehealthcare.com/hospitals/bristol-myers-squibb-becomes-12th-drug-maker-to-announce-340b-contract-pharmacy. Google Scholar
• Kwong WJ, Norton EC (2007) The effect of advertising on pharmaceutical innovation. Rev. Industry Organ. 31(3):221–236.Crossref, Google Scholar
• Larkin I, Ang D, Steinhart J, Chao M, Patterson M, Sah S, Wu T, et al. (2017) Association between academic medical center pharmaceutical detailing policies and physician prescribing. JAMA 317(17):1785.Crossref, Google Scholar
• Lawler EC, Skira MM (2022) Information shocks and pharmaceutical firms’ marketing efforts: Evidence from the Chantix black box warning removal. J. Health Econom. 81:102557.Crossref, Google Scholar
• Liu Q, Gupta S, Venkataraman S, Liu H (2016) An empirical model of drug detailing: Dynamic competition and policy implications. Management Sci. 62(8):2321–2340.Link, Google Scholar
• Manchanda P, Xie Y, Youn N (2008) The role of targeted communication and contagion in product adoption. Marketing Sci. 27(6):961–976.Link, Google Scholar
• Marquardt K, Ryan C (2023) The role of information in pharmaceutical advertising: Theory and evidence. Federal Reserve Bank of Chicago, Chicago.Google Scholar
• Mizik N, Jacobson R (2004) Are physicians “easy marks”? Quantifying the effects of detailing and sampling on new prescriptions. Management Sci. 50(12):1704–1715.Link, Google Scholar
• Montoya R, Netzer O, Jedidi K (2010) Dynamic allocation of pharmaceutical detailing and sampling for long-term profitability. Marketing Sci. 29(5):909–924.Link, Google Scholar
• Morton FMS (2000) Barriers to entry, brand advertising, and generic entry in the US pharmaceutical industry. Internat. J. Industrial Organ. 18(7):1085–1104.Crossref, Google Scholar
• Mulligan K (2021) The 340B drug pricing program: Background, ongoing challenges and recent developments. Schaeffer Center White Paper Series, University of Southern California Leonard D. Schaeffer Center for Health Policy and Economics, Los Angeles, CA.Google Scholar
• Narayanan S, Manchanda P (2009) Heterogeneous Learning and the targeting of marketing communication for new products. Marketing Sci. 28(3):424–441.Link, Google Scholar
• Parker ED, Lin J, Mahoney T, Ume N, Yang G, Gabbay RA, ElSayed NA, Bannuru RR (2024) Economic costs of diabetes in the U.S. in 2022. Diabetes Care 2 47(1):26–43.Google Scholar
• Philipson T, Durie T (2021a) The evidence base on the impact of price controls on medical innovation. Becker Friedman Institute Working paper, University of Chicago, Chicago.Google Scholar
• Philipson T, Durie T (2021b) Issue brief: The impact of HR 5376 on biopharmaceutical innovation and patient health. University of Chicago, 29 November 2021, https://bpb-us-w2.wpmucdn.com/voices.uchicago.edu/dist/d/3128/files/2021/08/Issue-Brief-Drug-Pricing-in-HR-5376-11.30.pdf.Google Scholar
• Pierson B (2023) Drugmakers prevail in dispute over U.S. discount drug program. Reuters (January 30), https://www.reuters.com/legal/drugmakers-prevail-dispute-over-us-discount-drug-program-2023-01-30/.Google Scholar
• Regan TL (2008) Generic entry, price competition, and market segmentation in the prescription drug market. Internat. J. Industrial Organ. 26(4):930–948.Crossref, Google Scholar
• Shapiro BT (2016) Estimating the cost of strategic entry delay in pharmaceuticals: The case of Ambien CR. Quant. Marketing Econom. 14(3):201–231.Crossref, Google Scholar
• Shapiro BT (2018) Informational shocks, off-label prescribing, and the effects of physician detailing. Management Sci. 64(12):5925–5945.Link, Google Scholar
• Sun L, Abraham S (2021) Estimating dynamic treatment effects in event studies with heterogeneous treatment effects. J. Econom. 225(2):175–199.Crossref, Google Scholar
• Van Der Schans S, Vondeling GT, Cao Q, Van Der Pol S, Visser S, Postma MJ, Rozenbaum MH (2021) The impact of patent expiry on drug prices: Insights from the Dutch market. J. Market Access Health Policy 9(1):1849984.Crossref, Google Scholar
• Yurukoglu A, Liebman E, Ridley DB (2017) The role of government reimbursement in drug shortages. Amer. Econom. J. Econom. Policy 9(2):348–382.Crossref, Google Scholar